BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 34180274)

  • 1. Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk.
    Brosnahan SB; Chen XJC; Chung J; Altshuler D; Islam S; Thomas SV; Winner MD; Greco AA; Divers J; Spiegler P; Sterman DH; Parnia S
    Ann Pharmacother; 2022 Mar; 56(3):237-244. PubMed ID: 34180274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19).
    Rodríguez-Baño J; Pachón J; Carratalà J; Ryan P; Jarrín I; Yllescas M; Arribas JR; Berenguer J; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
    Clin Microbiol Infect; 2021 Feb; 27(2):244-252. PubMed ID: 32860964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Use of High-Dose Corticosteroids Versus Low-Dose Corticosteroids With and Without Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome.
    Katz A; Altshuler D; Papadopoulos J; Amoroso N; Goldenberg R; Tarras E; Krolikowski K; Hagedorn J; Fridman D; Chen XJC; Iturrate E; Brosnahan SB
    Ann Pharmacother; 2023 Jan; 57(1):5-15. PubMed ID: 35590468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital.
    Van den Eynde E; Gasch O; Oliva JC; Prieto E; Calzado S; Gomila A; Machado ML; Falgueras L; Ortonobes S; Morón A; Capilla S; Navarro G; Oristrell J; Cervantes M; Navarro M
    Infect Dis (Lond); 2021 Apr; 53(4):291-302. PubMed ID: 33620019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low dose vs high dose tocilizumab in COVID-19 patients with hypoxemic respiratory failure.
    Chung J; Brosnahan SB; Islam S; Altshuler D; Spiegler P; Li WK; Wang WM; Chen XJC
    J Crit Care; 2023 Aug; 76():154291. PubMed ID: 37043893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm.
    Narain S; Stefanov DG; Chau AS; Weber AG; Marder G; Kaplan B; Malhotra P; Bloom O; Liu A; Lesser ML; Hajizadeh N;
    Chest; 2021 Mar; 159(3):933-948. PubMed ID: 33075378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mortality Rates Among Hospitalized Patients With COVID-19 Infection Treated With Tocilizumab and Corticosteroids: A Bayesian Reanalysis of a Previous Meta-analysis.
    Albuquerque AM; Tramujas L; Sewanan LR; Williams DR; Brophy JM
    JAMA Netw Open; 2022 Feb; 5(2):e220548. PubMed ID: 35226077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reply: Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk.
    Chen XJC; Altshuler D; Spiegler P; Brosnahan SB
    Ann Pharmacother; 2022 Apr; 56(4):507-508. PubMed ID: 34330173
    [No Abstract]   [Full Text] [Related]  

  • 9. Comment: Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk.
    Bissell BD; Mefford B; Donaldson JC
    Ann Pharmacother; 2022 Apr; 56(4):505-506. PubMed ID: 34330160
    [No Abstract]   [Full Text] [Related]  

  • 10. Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study.
    Russo G; Solimini A; Zuccalà P; Zingaropoli MA; Carraro A; Pasculli P; Perri V; Marocco R; Kertusha B; Del Borgo C; Del Giudice E; Fondaco L; Tieghi T; D'Agostino C; Oliva A; Vullo V; Ciardi MR; Mastroianni CM; Lichtner M
    PLoS One; 2021; 16(9):e0257376. PubMed ID: 34506608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.
    Declercq J; Van Damme KFA; De Leeuw E; Maes B; Bosteels C; Tavernier SJ; De Buyser S; Colman R; Hites M; Verschelden G; Fivez T; Moerman F; Demedts IK; Dauby N; De Schryver N; Govaerts E; Vandecasteele SJ; Van Laethem J; Anguille S; van der Hilst J; Misset B; Slabbynck H; Wittebole X; Liénart F; Legrand C; Buyse M; Stevens D; Bauters F; Seys LJM; Aegerter H; Smole U; Bosteels V; Hoste L; Naesens L; Haerynck F; Vandekerckhove L; Depuydt P; van Braeckel E; Rottey S; Peene I; Van Der Straeten C; Hulstaert F; Lambrecht BN
    Lancet Respir Med; 2021 Dec; 9(12):1427-1438. PubMed ID: 34756178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Timing of corticosteroids impacts mortality in hospitalized COVID-19 patients.
    Bahl A; Johnson S; Chen NW
    Intern Emerg Med; 2021 Sep; 16(6):1593-1603. PubMed ID: 33547620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness.
    Rubio-Rivas M; Ronda M; Padulles A; Mitjavila F; Riera-Mestre A; García-Forero C; Iriarte A; Mora JM; Padulles N; Gonzalez M; Solanich X; Gasa M; Suarez-Cuartin G; Sabater J; Perez-Fernandez XL; Santacana E; Leiva E; Ariza-Sole A; Dallaglio PD; Quero M; Soriano A; Pasqualetto A; Koo M; Esteve V; Antoli A; Moreno-Gonzalez R; Yun S; Cerda P; Llaberia M; Formiga F; Fanlo M; Montero A; Chivite D; Capdevila O; Bolao F; Pinto X; Llop J; Sabate A; Guardiola J; Cruzado JM; Comin-Colet J; Santos S; Jodar R; Corbella X
    Int J Infect Dis; 2020 Dec; 101():290-297. PubMed ID: 33035673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic corticosteroids for the treatment of COVID-19.
    Wagner C; Griesel M; Mikolajewska A; Mueller A; Nothacker M; Kley K; Metzendorf MI; Fischer AL; Kopp M; Stegemann M; Skoetz N; Fichtner F
    Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014963. PubMed ID: 34396514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.
    Salvarani C; Dolci G; Massari M; Merlo DF; Cavuto S; Savoldi L; Bruzzi P; Boni F; Braglia L; Turrà C; Ballerini PF; Sciascia R; Zammarchi L; Para O; Scotton PG; Inojosa WO; Ravagnani V; Salerno ND; Sainaghi PP; Brignone A; Codeluppi M; Teopompi E; Milesi M; Bertomoro P; Claudio N; Salio M; Falcone M; Cenderello G; Donghi L; Del Bono V; Colombelli PL; Angheben A; Passaro A; Secondo G; Pascale R; Piazza I; Facciolongo N; Costantini M;
    JAMA Intern Med; 2021 Jan; 181(1):24-31. PubMed ID: 33080005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of pulse-dose and high-dose corticosteroids with no corticosteroid treatment for COVID-19 pneumonia in the intensive care unit.
    Yaqoob H; Greenberg D; Hwang F; Lee C; Vernik D; Manglani R; Wang Z; Murad MH; Chandy D; Epelbaum O
    J Med Virol; 2022 Jan; 94(1):349-356. PubMed ID: 34542192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors and combined use of tocilizumab and corticosteroids in a Spanish cohort of elderly COVID-19 patients.
    Duarte-Millán MA; Mesa-Plaza N; Guerrero-Santillán M; Morales-Ortega A; Bernal-Bello D; Farfán-Sedano AI; García de Viedma-García V; Velázquez-Ríos L; Frutos-Pérez B; De Ancos-Aracil CL; Soria Fernández-Llamazares G; Toledano-Macías M; Cristóbal-Bilbao R; Luquín-Ciuro N; Marrero-Francés J; Piedrabuena-García SI; Satué-Bartolomé JA; Gonzalo-Pascua S; Rivilla-Jiménez M; Carpintero-García L; Ayala-Larrañaga I; García-Bermúdez V; Lara-Montes C; Llerena-Riofrío ÁR; RIvas-Prado L; Walter S; Escriba-Barcena A; San Martín López JV; Ruíz-Giardín JM
    J Med Virol; 2022 Apr; 94(4):1540-1549. PubMed ID: 34845754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anakinra or high-dose corticosteroids in COVID-19 pneumonia patients who deteriorate on low-dose dexamethasone: an observational study of comparative effectiveness.
    Langer-Gould A; Xu S; Myers LC; Chen A; Greene JD; Creekmur B; Bruxvoort K; Adams JL; Liu V; Gould MK
    Int J Infect Dis; 2023 Jan; 126():87-93. PubMed ID: 36403818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.